Icon

Ayala Pharmaceuticals Inc. Stock Analysis and Price Target COMMON STOCK | Biotechnology | OTC

stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.82

0.00 (0.00)%

USD 4.23M

254.00

USD 4.00(+387.80%)

N/A

Icon

ADXS

Ayala Pharmaceuticals Inc. (USD)
COMMON STOCK | OTC
USD 0.82
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 4.23M

N/A

USD 0.82

Ayala Pharmaceuticals Inc. Stock Forecast

USD 4.00
(+387.80%)

Based on the Ayala Pharmaceuticals Inc. stock forecast from 1 analysts, the average analyst target price for Ayala Pharmaceuticals Inc. is USD 4.00 over the next 12 months. Ayala Pharmaceuticals Inc. ’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ayala Pharmaceuticals Inc. is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Ayala Pharmaceuticals Inc. ’s stock price was USD 0.82. Ayala Pharmaceuticals Inc. ’s stock price has changed by +0.00% over the past week, -6.29% over the past month and -79.80% over the last year.

No recent analyst target price found for Ayala Pharmaceuticals Inc.
No recent average analyst rating found for Ayala Pharmaceuticals Inc.

Company Overview Ayala Pharmaceuticals Inc.

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma ...Read More

https://www.advaxis.com

9 Deer Park Drive, Monmouth Junction, NJ, United States, 08852

0

October

USD

USA

Adjusted Closing Price for Ayala Pharmaceuticals Inc. (ADXS)

Loading...

Unadjusted Closing Price for Ayala Pharmaceuticals Inc. (ADXS)

Loading...

Share Trading Volume for Ayala Pharmaceuticals Inc. Shares

Loading...

Compare Performance of Ayala Pharmaceuticals Inc. Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ADXS

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Ayala Pharmaceuticals Inc. (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF
Novo Nordisk A/S -1.58 (-1.50%) USD462.13B 43.02 3.65

ETFs Containing ADXS

Symbol Name ADXS's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Ayala Pharmaceuticals Inc. (ADXS) Stock

Based on ratings from 1 analysts Ayala Pharmaceuticals Inc. 's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.

Unfortunately we do not have enough data on ADXS's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for ADXS is USD 4.00 over the next 12 months. The maximum analyst target price is USD 4 while the minimum anlayst target price is USD 4.

Unfortunately we do not have enough data on ADXS's stock to indicate if its overvalued.

The last closing price of ADXS's stock was USD 0.82.

The most recent market capitalization for ADXS is USD 4.23M.

Based on targets from 1 analysts, the average taret price for ADXS is projected at USD 4.00 over the next 12 months. This means that ADXS's stock price may go up by +387.80% over the next 12 months.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...